Home | Feedback | Contact Us | Site Map | Privacy Statement
Organogenesis Inc. Living Technology
 
 
We'd Like to Learn...

more about you to help
us improve our products
and services.

 
 
 

Press Releases and Announcements

  • (Canton, Mass. / Washington D.C.) –
    April 17, 2008

    Organogenesis, Inc. to Develop Regenerative Medicine Therapies for U.S. Military Battlefield Injuries
    Consortium wins grant to form new Armed Forces Institute of Regenerative Medicine (AFIRM).
    (Read full version of this press release...)

  • (Canton, Mass) – April 3rd, 2008
    Governor Patrick Announces Life Sciences Initiative Victory With Organogenesis' New Headquarters
    Regenerative Medicine leader to expand space and employees in Massachusetts, encompassing over 250,000 square feet for new global headquarters.

  • (Canton, Mass) – March 17, 2008
    Organogenesis Names Regenerative Medicine Expert Dr. Damien Bates Vice President, Medical Affairs
    Organogenesis, Inc., announced today that Damien Bates, MD, PhD, FRACS (Plast.), has joined the company as vice president of medical affairs.
    (Read full version of this press release...)

  • (Canton, Mass) – February 11, 2008
    Organogenesis Debuts Educational Campaign for Sufferers of Chronic Leg and Foot Ulcers
    Organogenesis, Inc., the first company to successfully mass-produce living regenerative medicine products, is again breaking new ground by launching the first-ever direct-to-consumer (DTC)—educational campaign for a living cell-based therapy.
    (Read full version of this press release...)

  • (Canton, Massachusetts / Baton Rouge, Louisiana) – January 25, 2008
    Organogenesis, Inc. Announces Acquisition of NanoMatrix, Inc.
    Organogenesis, Inc., the world's most successful regenerative medicine company, announced today the strategic acquisition of Baton Rouge-based NanoMatrix, Inc.
    (Read full version of this press release...)

  • (Canton, Mass/Shanghai) – December 10, 2007
    Organogenesis, Inc. Signs Memorandum of Understanding with Chinese Regenerative Medicine Company
    Organogenesis, Inc., the world's most successful regenerative medicine company, announced today that it has signed a memorandum of understanding with China’s National Tissue Engineering Center (NTEC), a leading stem cell and regenerative medicine consortium, headquartered in Shanghai.
    (Read full version of this press release...)

  • (London, England/Canton, Massachusetts) – November 16, 2007
    Stephen Farrell of Organogenesis Addresses Life Sciences Leaders at 5th Annual Commercial Translation for Regenerative Medicine in London
    Organogenesis, Inc., the world's most successful regenerative medicine company, has announced that Stephen Farrell, Vice President of Marketing will address the 5th Annual Commercial Translation for Regenerative Medicine conference, taking place this week in London.
    (Read full version of this press release...)

  • (Leipzig, Germany / Canton, Massachusetts) – October 18, 2007
    CEO of World’s Leading Regenerative Medicine Company, Organogenesis, Gives Keynote Address at World Congress of Regenerative Medicine in Germany
    The prestigious 3rd Annual World Congress of Regenerative Medicine is kicking off today in Leipzig, Germany with an opening keynote address from Geoff MacKay, CEO of Organogenesis, Inc.
    (Read full version of this press release...)

  • (Canton, MA) – July 9, 2007
    Bioresorbable Collagen Scaffold Placed Inside the Heart Revolutionizes Treatment
    BioSTAR® (NMT Medical, Boston, MA), a device that incorporates a bioresorbable collagen scaffold used to treat patent foramen ovale (PFO) has received regulatory approval in Canada and Europe.
    (Read full version of this press release...)

  • (Canton, MA) – May 31, 2007
    On Heels of Life Sciences Initiative, Governor Patrick Announces Organogenesis to Expand in Massachusetts
    World's first profitable regenerative medicine company to grow in Massachusetts due to state's newly unveiled life science initiative.
    (Read full version of this press release...)

  • (Canton, MA) – May 7, 2007
    CEO of World's First Profitable Regenerative Medicine Company, Organogenesis, Details Path To Profitability For The Regenerative Medicine Field
    Geoff MacKay, CEO of ORGANOGENESIS, Inc., will present at the world's leading biotech conference, BIO 2007 on May 8, 2007 in Boston, MA.
    (Read full version of this press release...)

  • (Canton, MA) – January 2006
    Organogenesis Inc. Announces Further Sales Force Expansion
    Due to the rapid uptake of Apligraf® , the world's leading tissue regeneration product, Organogenesis announces the third sales force expansion in the last two years. The unique skills required to integrate a cell-based tissue regeneration product into the health care system requires sales specialists capable of providing a breadth and depth of the most relevant scientific learnings to top wound specialists around the country.

  • (Canton, MA) – April 2005
    Same Apligraf® Cell Viability & Structure….Now with a 10 Day Shelf Life!

    Organogenesis Inc. announces that its lead product Apligraf® now has an extended shelf life of 10 days in the hands of wound healing specialists. Apligraf® is the only tissue regeneration product approved by FDA to treat both venous leg ulcers and diabetic foot ulcers. The significantly longer shelf life of this living, cell-based product provides greater convenience to the wound healing centers around the country who routinely order Apligraf® to close wounds faster than conventional approaches.

  • (Canton, MA) – February 2005
    Apligraf® Treats Over 100,000 Patients in the USA
    Apligraf® , the world's leading tissue regeneration product, has been applied to over 100,000 patients. This constitutes over two-thirds of all living, cell-based product applications across all therapeutic areas. The initial FDA approvals for Apligraf® ushered in the new era of tissue regeneration. This "100,000 patient check-up" highlights the growing success the product has achieved as a key technology in closing chronic wounds.

  • (Canton, MA) – January 2005
    Organogenesis Inc. Launched Major Study to Treat Pressure Ulcers

    Pressure ulcers (also known as "bedsores") arise as a result of skin breakdown, usually over bony prominences, occurring as a result of prolonged pressure. Patients with limited mobility, such as those bedridden, are particularly prone to pressure ulcers. Pressure ulcers can occur most anywhere in the body but are especially troublesome in the pelvic area. The severity of pressure ulcers can range from relatively minor skin redness (Stage I) to major wounds that extend all the way to bone (Stage IV). Organogenesis is studying the use of Apligraf® compared to conventional treatment for treatment of Stage III pressure ulcers located in the pelvic area. Fifteen medical centers are participating in this groundbreaking Phase III study.